Table 1.
Demographic and clinical characteristics of the patients with AAV and sarcoidosis.
| AAV, n = 16 | Sarcoidosis, n = 21 | p-value | |
|---|---|---|---|
| Female, n (%) | 11 (69) | 15 (71) | 1.00 |
| Age, yrs, median (IQR) | 78 (75–81) | 62 (45–73) | 0.0002 |
| Smoking: | |||
| Never smokers, n (%) | 11 (69) | 11 (52) | |
| Former smokers, n (%) | 3 (19) | 4 (19) | 0.5234* |
| Current smokers, n (%) | 2 (13) | 6 (29) | |
| MPO-ANCA-positive, n (%) | 13 (81) | ||
| MPO-ANCA titer, U/mL (range) | 43 (15–172) | — | |
| PR3-ANCA positive, n (%) | 1 (6) | ||
| PR3-ANCA titer, U/mL | 34 (n = 1) | — | |
| GPA/MPA | 2/14 | — | |
| AAV involvements, n (%): | |||
| Lung | 16 (100) | — | |
| Kidney | 7 (44) | — | |
| ENT | 1 (6) | — | |
| Nerve | 3 (19) | — | |
| Eye | 1 (6) | — | |
| Joint | 2 (13) | — | |
| BVAS, median (IQR) | 16 (8–19) | — | |
| Sarcoidosis involvements, n (%): | |||
| Lung | — | 18 (86) | |
| Eye | — | 11 (52) | |
| Lymph node | — | 18 (86) | |
| Skin | — | 5 (24) | |
| Heart | — | 3 (14) | |
| Pancreas | — | 1 (5) | |
| Bronchoscopy: | |||
| Recovery percentage of BALF (%), median (IQR) | 34 (31–44) | 53 (48–62) | <0.0001 |
| BAL fluid cell concentration (105 cells/mL), median (IQR) | 2.9 (2.0–6.0) | 2.2 (1.9–3.5) | 0.2102 |
| Macrophages (%), median (IQR) | 52 (46–61) | 63 (48–83) | 0.1352 |
| Lymphocytes (%), median (IQR) | 12 (6–28) | 36 (14–50) | 0.0052 |
| Neutrophils (%), median (IQR) | 22 (5–45) | 1 (0–3) | <0.0001 |
| Eosinophils (%), median (IQR) | 0 (0–3) | 0 (0–2) | 0.5302 |
*Cochran-Armitage test among never smokers, former smokers, and current smokers. AAV: ANCA-associated vasculitis, ANCA: antineutrophil cytoplasmic antibody, BALF: bronchoalveolar lavage fluid, ENT: ear: nose: throat, IQR: interquartile range, MPO: myeloperoxidase, PR3: proteinase 3.